Product nomenclature — Human insulin produced by recombinant DNA technology is commonly marketed under which generic name?

Introduction / Context:Brand and generic naming conventions help students recognize widely used biopharmaceuticals. Recombinant human insulin revolutionized diabetes care, and its early trade name is still often used as a shorthand in textbooks and examinations.

Given Data / Assumptions:

• “Humulin” refers to human insulin made via recombinant DNA technology.
• Animal-sourced insulins were previously standard but are now less common.
• Multiple brands exist, but Humulin is historically emblematic.

Concept / Approach:Humulin denotes bioidentical human insulin produced in microbial hosts (E. coli or yeast). It replaced bovine/porcine insulin, improving immunogenicity profiles and supply reliability. Variants (regular, NPH, premixes) share the underlying recombinant origin.

Step-by-Step Solution:

Verification / Alternative check:Pharmacology texts and formularies list Humulin R and Humulin N as standard preparations of recombinant human insulin.

Why Other Options Are Wrong:

• H insulin/R insulin/huinsulin: not standard trade names.
• Insugen-RNA: fabricated in this context; not a conventional product name.

Common Pitfalls:Confusing “human insulin” (a molecule) with specific analogs (insulin lispro, aspart, glargine) that are engineered variants, not the original Humulin.

Final Answer:Humulin.